Theralase Technologies Inc. V.TLT

RE:RE:RE:RE:RE:RE:tradeable warrants

[99942Apophis]

Eoganacht wrote: The interim trial results are far from "so so"

Keytruda was approved by the FDA  for NMIBC with a durable complete response rate of 18%
Adstiliadrin was recently approved by the FDA with a a durable complete response rate of 23%
Our current (but steadily improving) interim durable complete response rate of 33% along with the absence of trial-related adverse events makes 2-treatment Ruvidar PDT  the best in class stand-alone treatment for BCG-unresponsive NMIBC. We don't need 100% efficacy in order to save many more patients lives and make us all rich.

There is no "insistence" on using the laser to activate PDCs

Nobody is insisting on anything. The technogy is just not ready yet and there may still be obstacles to overcome. Some of the issues and proposed solutions of x-ray activated PDT are outlined in Dr. McFarland and Dr. Lilge's recent paper: https://stockhouse.com/companies/bullboard?symbol=v.tlt&postid=35608406

"Using the laser beam" is not like using the paint brush.

Any cancer cells which escape immediate destruction should be taken care of by the patients own immune system since Ruvidar PDT induces immunogenic cell death.

bigkagan wrote: IMHO, their "so so" trial results so far stem from their insistence on using the laser to activate PDCs in the cancer cells. The laser beam misses lots of cancer cells in the top layer and pretty much all the cells in the lower layers. Using the laser beam is like using the paint brush - some spots always are left untouched. The x-rays are much more effective because they zap all the cancer cells. If I were a patient, I would demand an x-ray instead of a laser

In addition one can't make changes to a clinical trial already in progress, use of a different trigger device in my understanding would have to be done in a new trial. Please correct me if wrong.